EUROFINS PHARMACEUTICAL PRODUCT TESTING BELGIUM financials
A multi-period view of the public annual-account figures reported for EUROFINS PHARMACEUTICAL PRODUCT TESTING BELGIUM, with comparable measures and links to available source documents.
Company overviewRegistry number
0435237515
Fiscal coverage
2024–2025
Public sources
cbso_bulk
Data updated
Jul 27, 2026
Financial evidence
Latest movements for EUROFINS PHARMACEUTICAL PRODUCT TESTING BELGIUM
2025 versus 2024
- Operating line
- €1,889,206
- EBITDA
- €320,670
- Total assets
- €3,212,468
- Equity
- €816,310
-21.6%
-53.9%
-8.3%
0%
EBITDA margin +17% · Equity ratio +25.4%
Multi-year filings
Source: NBB/CBSOFiled annual accounts by fiscal year
Public regulator-filed figures across 2 years.
Fiscal year | Gross margin | EBITDA | Total assets | Equity | Filing |
|---|---|---|---|---|---|
| 202531 Dec 2025 | €1,889,206 | €320,670 | €3,212,468 | €816,310 | - |
| 202431 Dec 2024 | €2,410,982 | €696,050 | €3,504,020 | €816,310 | - |
Figures reproduce public filings and may use country-specific accounting definitions. They are not audited by Upswitch.